Review Article

Circular RNA Expression: Its Potential Regulation and Function in Abdominal Aortic Aneurysms

Yanshuo Han, Hao Zhang, Ce Bian, Chen Chen, Simei Tu, Jiahui Guo, Yihao Wu, Dittmar Böckler, and Jian Zhang

1School of Life and Pharmaceutical Science, Dalian University of Technology, Dalian, China
2Department of Cardiovascular Surgery, The General Hospital of the PLA Rocket Force, Beijing Normal University, Beijing, China
3School of Biomedical Sciences, The University of Queensland, Brisbane, Australia
4Department of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, Germany
5Department of Vascular Surgery, The First Hospital, China Medical University, Shenyang, China

Correspondence should be addressed to Yanshuo Han; yanshuohan@dlut.edu.cn, Dittmar Böckler; dittmar.boeckler@med.uni-heidelberg.de, and Jian Zhang; jianzhang@cmu.edu.cn

Received 22 March 2021; Accepted 30 May 2021; Published 30 June 2021

Academic Editor: Albino Carrizzo

Abdominal aortic aneurysms (AAAs) have posed a great threat to human life, and the necessity of its monitoring and treatment is decided by symptomatology and/or the aneurysm size. Accumulating evidence suggests that circular RNAs (circRNAs) contribute a part to the pathogenesis of AAAs. circRNAs are novel single-stranded RNAs with a closed loop structure and high stability, having become the candidate biomarkers for numerous kinds of human disorders. Besides, circRNAs act as molecular “sponge” in organisms, capable of regulating the transcription level. Here, we characterize that the molecular mechanisms underlying the role of circRNAs in AAA development were further elucidated. In the present work, studies on the biosynthesis, bibliometrics, and mechanisms of action of circRNAs were aims comprehensively reviewed, the role of circRNAs in the AAA pathogenic mechanism was illustrated, and their potential in diagnosing AAAs was examined. Moreover, the current evidence about the effects of circRNAs on AAA development through modulating endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs) was summarized. Through thorough investigation, the molecular mechanisms underlying the role of circRNAs in AAA development were further elucidated. The results demonstrated that circRNAs had the application potential in the diagnosis and prevention of AAAs in clinical practice. The study of circRNA regulatory pathways would be of great assistance to the etiologic research of AAAs.

1. Introduction

Abdominal aortic aneurysms (AAAs) frequently induce cardiovascular death among the elderly male population within various European and Asian countries [1–3]. AAAs are featured by permanent expansion and weakening of a localized abdominal aorta [4–6]. There are symptomatic, asymptomatic, and ruptured AAAs clinically [7]. As estimated by a UK study, 1.5% of its population has an AAA greater than 30 mm in size [8]. Besides, a USA multicenter aneurysm screening study has suggested that 4.6% of its population aged 65-74 suffers from an AAA [9]. In Sweden, the incidence of the AAA among male population aged above 65 is reported to be 1.8% [10]. Because of the lack of effective surgical methods and unpredictability of the disease, continuous enlargement of the aortic wall will lead to the wall rupture and serious bleeding, resulting in a death rate as high as 80% [11]. A majority of AAA cases are progressive and asymptomatic, which are usually discovered accidentally by the diagnostic imaging of other diseases. The survival of AAA patients after diagnosis has improved, but its morbidity and mortality rates show an ascending trend [3]. Generally,
the AAA-related mortality cannot be affected by AAA screening, but may be lowered by other factors like smoking less [12].

Conventionally, AAAs are mostly treated with elective retroperitoneal or open transperitoneal surgery [13], but now, the endovascular repair (EVAR) is recommended as a better alternative to open surgical repair [14–16]. Currently, no curative treatment is available for restricting AAA development and preventing AAA rupture [17], and the only strategy is to continuously monitor the aneurysm size before surgery [18].

The pathogenic mechanism of AAAs is complicated and involves multiple factors. Previous studies suggest that AAAs are associated with the weakened defective adventitial/medial arterial layers, like fibroblasts and smooth muscle cells (SMCs) [19–22]. Recently, research on human tissue and animal models indicates that the AAA occurrence arises from the dynamic vascular remodelling [23, 24]. Additionally, the critical pathological features of AAAs are oxidative stress (OS), vascular inflammation, aortic wall thinning due to the loss of vascular smooth muscle cells (VSMCs), and aortic extracellular matrix (ECM) decomposition [22, 24].

Due to strong gene expression regulation effects, epigenetic alterations, such as histone modification, DNA methylation, and noncoding RNA (ncRNA) modification [25–27], have been increasingly acknowledged as an importance contributor to AAA development. It has been proven that epigenetic modifications take place in the early embryogenesis and primordial cell development processes, but it is of great significance to explore the effects of these alterations in “later life.” In such, “later life” epigenetic modifications caused by the dietary intervention were analyzed [28]. Generally, ncRNAs can be divided into small ncRNAs and long ncRNAs (lncRNAs) according to the arbitrary threshold size of 200 nucleotides (nt). Among small ncRNAs, microRNAs (miRNAs) with a length of about 22 nt have been extensively investigated. By contrast, there is less studies on the functions of lncRNAs with a length of over 200 nt. Although ncRNAs have been demonstrated to regulate the interactions and activities of fibroblasts, vascular inflammatory cells, endothelial cells (ECs), and SMCs, the key factors resulting in AAA occurrence remain unidentified. According to a new eukaryotic gene expression feature discovered in 2012, circRNAs are ubiquitously expressed in genes previously considered to express linear ncRNAs or messenger RNAs (mRNAs) only. circRNAs are RNA molecules with a circular and covalently closed structure, which usually consist of exon sequences and can be spliced at the typical splice sites.

In particular, many articles have demonstrated the important roles of ncRNAs in cardiovascular diseases (CVDs), such as aortic dissection and AAAs. Meanwhile, circRNAs are also considered to exhibit certain effects on some CVDs, but their expression levels and roles in AAAs still remain unclarified.

In the present work, the roles of circRNAs in the occurrence and development of AAAs were illustrated, and their significance in treating AAAs was discussed. In addition, the regulation effect of circRNAs and their corresponding target genes on AAAs and the underlying mechanisms were also investigated. The ncRNAs that were previously recognized to be involved in several processes leading in AAAs were highlighted. The in-depth investigation on such circRNAs will shed lights on the prevention and treatment of AAAs, and these circRNAs may be used as candidate prognostic biomarkers and therapeutic targets for the prediction of the AAA incidence and the evaluation of patient prognosis.

2. Genetic Causes of AAA Pathogenesis

2.1. Mendelian Causes. A Mendelian factor that causes AAAs often refers to single-gene mutations [29]. Marfan syndrome can also induce AAAs, which is often accompanied by a family history. Marfan syndrome arises mainly from FBN1 gene mutation [30], accounting for an autosomal dominant genetic disorder. The TGFβR1, TGFβR2, and TGFβR3 gene mutations promote the production of matrix metalloproteinases (MMPs) and eventually lead to medial degradation [31]. Other syndromes can provoke the occurrence of aortic root aneurysms. In addition, some diseases derived from single-gene mutations affect ECM components of the aortic wall. The Ehlers Danlos syndrome, for instance, originates from COL3A1 gene mutation [32]. AAAs may be detected in cases who develop autosomal recessive disorders, such as pseudoxanthoma elasticum and homocystinuria, which stem from ABCC6 and CBS gene mutations, respectively [29].

2.2. Non-Mendelian Causes. There are various non-Mendelian factors leading to AAAs, including the ECM, endothelial cell (EC) specification, SMCs differentiation, inflammation, and cell adhesion.

2.2.1. ECM. The ECM is a complex network of macromolecular substances that supports and connects tissue as well as mediates tissue generation and cell physiological activities. The proteins of the Matrix Metalloproteinases (MMP) family can regulate the ECM turnover, which is related to the formation of genes that encode MMP and ECM components in AAAs. Besides, upregulated MMP-2 and MMP-9 levels can be detected within human AAA tissue [33, 34]. Moreover, the single-nucleotide polymorphisms (SNPs) rs3025058 in MMP-3 and rs2252070 in MMP-13 are suggested to lead to a higher AAA risk [35]. Inhibiting the ablation of MMP-3 can promote aneurysm formation. Additionally, the G allele of rs2252070 also contributes to a higher AAA risk [36].

2.2.2. SMC Differentiation. AAAs are related to rs1795061 localized at around 40 kb upstream of the SMYD2 transcription start site [37]. SMYD proteins belong to the lysine methyltransferases, and they play a vital part in the regulation of cardiac and skeletal morphogenesis [38]. According to a recent report, SMYD2 is possibly associated with the pathogenic mechanism of AAAs [39]. Importantly, Toghill et al. evaluated DNA methylation within VSMCs collected from AAA patients using targeted bisulphite next-generation sequencing (NGS) for the first time. They found evident DNA hypomethylation within the promoter region of SYMD2 gene among AAA cases and a close association between the average methylation degree of CpGs and gene
expression levels [40]. Typically, methylation of the SMYD2 promoter region may be related to AAA development, rather than its progression [40].

2.2.3. EC Specification. In the study of Jones et al., the SNP rs2836411, an AAA risk variation localized at 21q22.2 in the intrinsic region of ERG gene, was detected [37]. ERG can encode one transcription factor (TF) existing in ECs and hematopoietic cells (HPCs) under normal conditions. ERG plays a part in the vascular development mediated by the vascular endothelial growth factor (VEGF/mitogen-activated protein kinase (MAPK)) and also regulates new vessel formation [41]. The minor (T) allele of rs2836411 correlates with a greater risk of AAAs in several populations [42].

2.2.4. Inflammation. CD4+ T cells are found to accumulate on the aneurysm wall, and AAA-related SNPs are detected in some human genes encoding such critical inflammatory components. AAA patients show an increased circulating IL-6 level. IL-6 is secreted by the aneurysm, and its expression level is related to the aneurysm surface area. Angiotensin II can affect AAAs by acting on the IL-6 signaling pathway in mice.

3. Epigenetic Regulation of AAAs

Epigenetic modifications are induced by developmental or environmental factors. They do not change the genetic code but can regulate the tissue- or context-specific expression of information encoded in DNA [43, 44]. Traditional views hold that epigenetic markers are stable, which may be transmitted to progeny, and control the steady differentiation of different types of cells with significantly diverse gene expression profiles [45]. On the whole, epigenetic alterations are divided into 3 major types: (1) DNA methylation, (2) histone modifications, and (3) ncRNAs. Of them, ncRNAs will not bring about heritable alterations, but they are usually deemed as epigenetic mechanisms due to their vital regulating functions in the genome nonprotein-coding regions. A small number of studies have revealed the important role of the above-mentioned three categories of epigenetic modifications in AAA occurrence [25–27, 40, 46, 47].

3.1. DNA Methylation in AAAs. DNA methylation, one of the potent epigenetic mechanisms, is crucial in preserving the DNA structure, deactivating the X chromosome and maintaining chromosome stability. Besides, DNA methylation also modulates components (retrotransposons and transposons) and regulates gene levels [48]. It is claimed that some key processes contributing to AAA occurrence may be affected by DNA methylation. Generally speaking, DNA methylation is catalyzed by the DNA methyltransferases (DNMTs), including DNMT1 (maintenance enzymes) and DNMT3 (de novo enzymes). Researchers are focusing on DNA methylation in T lymphocyte, and the analysis of different types of vascular cells, such as ECs, SMCs, and adventitial cells, may provide more targets specific to aneurysms [47]. Increasing evidence suggests that T cell dysfunction, especially the reduced suppression of CD4+ CD25+ regulatory T cells, induces AAA occurrence [46]. Apart from DNA hypomethylation, DNA hypermethylation in certain gene promoter regions also contributes to AAA occurrence. This opinion is addressed in a recent article, which evaluates the global methylation level in AAA patient-derived peripheral blood mononuclear cells (PBMCs) and compares it with that in PBMCs from normal subjects [40]. The study conducted by Skorvanova et al. revealed no association of AAA development with DNA methylation of gelatinases and their tissue inhibitors (e.g., MMP2, TIMP2, TIMP1, and MMP9) [49].

3.2. Histone Acetylation in AAAs. Gene activation and inactivation depend on specific signatures of histone modifications in critical enhancer or promoter gene regions. Such modifications are harbored in histone deacetylases, histone acetylases, together with methyltransferases [50]. The findings of our work show that the abnormal epigenetic modifications in AAAs are the changed expression of lysine [K] histone acetyltransferases (KATs) and related histone acetylation. The above results shed novel lights on the pathogenic mechanism of AAAs [26]. As suggested in another study, the levels of some histone deacetylases (HDACs) in AAA mice and ApoE−/− AAA mice infused with Angiotensin (Ang) II are higher than those in normal controls [51]. As a class III HDAC, Sirtuin 1 (SIRT1) is also studied for its role in AAA occurrence and the mechanisms underlying vascular inflammation and aging. The result suggests that SIRT1 in VSMCs provides a new therapeutic target for preventing AAA occurrence [52].

3.3. ncRNAs in AAAs. It has been established that over 97% of the genome can encode the noncoding transcripts, most of which can be processed into short ncRNAs (such as miRNAs) and IncRNAs. There are various factors leading to AAAs, and the pathology and pathogenic mechanisms of AAAs at the molecular level remain largely unclear. Therefore, it will become a novel research direction to investigate the AAA etiology at the epigenetic level. Studies have shown that ncRNAs take part in the AAA genesis. Many ncRNAs are differentially expressed in AAA patients and regulate gene expression at transcriptional and posttranscriptional levels. The regulatory pathways of some ncRNAs have also been confirmed, which is conducive to the study of other molecular mechanisms [27, 53–56].

3.3.1. miRNAs in AAAs. MiRNAs are short (21-23-nt-long) RNA molecules existing in eukaryotes, capable of regulating the expression of other genes [57]. They are ncRNAs and control posttranscriptional expression by specifically binding with mRNAs [58]. In general, negative regulation is mainly achieved by the degradation of mRNAs or inhibition of mRNAs expression. MiRNAs can be regulated by a variety of approaches. A miRNA may possess several target genes, while several miRNAs may modulate the same target gene. MiRNAs adjust target gene expression of one or more genes through forming complicated regulatory networks [59, 60]. MiRNAs are closely associated with the AAA pathogenic mechanism [61]. In AAA patients, miRNAs affect the pathogenesis of AAAs by forming networks to regulate the ECM turnover, MMP family, different inflammatory components, and vascular smooth muscle development [62–65].
The most typical type of miRNAs is miRNA-29 family members, which promote the AAA formation by regulating fibrosis and the ECM. miRNA-29 inhibits the expression of several ECM proteins and antiapoptotic factors in SMCs, thereby boosting the aneurysm generation [66, 67]. Studies have confirmed that AAAs with overexpressed miRNA-29b are more prone to rupture. Reducing the miRNA-29b levels can lower the probability of AAA rupture. Upregulation of miRNA-21 can be detected in AAA patients and mouse models. Overexpressed miRNA-21 can downregulate the phosphatase and tensin homolog (PTEN) levels, thereby inhibiting the viability of SMCs and maintaining vessel wall stability in mouse models with elastin degradation-induced aneurysms [68]. Moreover, Wang et al. have observed that the anti-miRNA-21 drug-eluting stent successfully prevents in-stent myointimal hyperplasia in a humanized rat model, further highlighting the complex roles of miRNA-21 in various vascular pathologies [69]. Furthermore, a decline in miRNA-33 leads to attenuated p38 and JNK (c-Jun N-terminal kinase) signals as a result of increased ABCA1 expression, the inhibition effect of CaCl2 and Ang II-induced aneurysm formation in mice [70]. In conclusion, the expression level of miRNAs is tightly bound to the AAA development. Therefore, it is of great significance to study the pathogenesis of AAAs.

3.3.2. lncRNAs in AAAs. lncRNAs are a type of ncRNAs longer than 200 nt without the protein encoding function, and they are involved in regulating numerous processes [71]. In recent years, many research groups have been devoted to the study of lncRNAs and their pathological function [72]. However, a lot of efforts and in-depth exploration are still required in this field. lncRNAs serve as a gene domain and TF scaffold, guiding the transcription complex of activators and inhibitors to the regulatory region to regulate transcription [73, 74]. One lncRNA associated with the AAA is H19. The H19 level in AAA samples is higher than that in normal controls, and inhibiting the expression of H19 arrests the growth of AAAs [53]. H19 seems to affect the pathogenesis of AAAs through inflammation [55]. Another study has shown that PVT1, an lncRNA, is upregulated in AAA patients. Overexpression of PVT1 promotes apoptosis of VSMCs and degradation of the ECM [75], and PVT1 knockout in vitro notably reduces the incidence of AAAs. It further confirms that PVT1 promotes the formation of AAAs. lncRNAs can also affect AAAs via acting on the development and differentiation of SMCs. The representative example is Inc-Ang362, which enhances the proliferation of VSMCs [76]. Moreover, relevant studies have proven that SMILR can regulate the migration and proliferation of VSMCs, and SMILR knockout restrains the proliferation of SMCs [77], indicating that lncRNAs also play an important part in AAA occurrence and progression. Decreased plasma levels of SMILR have been observed in TAA cases [78].

3.3.3. circRNAs in AAAs. Like lncRNAs, circRNA transcripts have been a recent addition to the functionally relevant ncRNAs in our genomic landscape. They have long been disregarded since their discovery in the 1990s due in part to a limitation in their detection method, but the emerging novel bioinformatics and deep RNA sequencing approaches provide the foundation for circRNA research [79]. Recent studies suggest that there are many endogenous circRNAs in mammalian cells, and some of them show high abundances and evolutionary conservation. circRNAs initially have been shown to mediate miRNA functions (e.g., via sponging) and control important events in transcription (e.g., RNA folding and endonuclease protection) [80]. At present, circRNAs are proven to be stable, endogenous and functional ncRNAs abundant in mammalian cells [81]. They may be generated through directly ligating the 3′ and 5′ ends of linear RNAs by means of back-splicing [82]. The downstream 5′ splice site (donor) will bind to the upstream 3′ site (acceptor) or serve as the intermediate during RNA processing (Figure 1). Not every circRNA possesses many miRNA binding sites, so it remains controversial whether miRNAs are suppressed by circRNAs.

3.3.4. Bibliometrics of ncRNAs in AAAs. Firstly, we explored the relationship between publication volume and time in Figure 2(a), the abscissa is the time series, and the ordinate is publication volume. The purple dot represents the annual publication volume for publication of circRNAs, corresponding to the right ordinate axis. Meanwhile, the red block represents the annual publication volume of “ncRNAs and AAAs,” corresponding to the left ordinate axis. Moreover, green triangle represents the annual publication volume of “circRNAs and AAAs” and also corresponds to left ordinate axis. From 2009 to 2020, the number of papers published on “ncRNAs and AAAs” has increased year by year. There are large quantities of papers on circRNAs, up to more than 2000 papers, but few about the relationship between “circRNAs and AAAs,” but they are generally close. The past few years have witnessed an ascending trend (Figure 2(a)).

Then, we also explored the relationship between publication volume and time for ncRNA in Figure 2(b). The cyan dot represents the annual publication volume of circRNAs corresponding to the right ordinate axis, the blue block represents the annual publication volume of miRNAs corresponding to the left ordinate axis, and the orange triangle represents the annual publication volume of lncRNAs corresponding to left ordinate axis. From 2000 to 2020, there are great many papers published on ncRNAs (circRNAs, lncRNAs, and miRNAs) annually, and the total number is still climbing. The miRNA publications account for the largest part of the total number of published papers, up to more than 15000 publications, while circRNA publications take up the smallest share (Figure 2(b)). The above data imply that the relationship between “circRNAs and AAAs” may become a research hot-spot and the international research direction in the future.

Keyword analysis is relatively essential to the research of the entire paper. It can help us to figure out the research direction. Figure 3(a) is the tag view of keywords, which reflects the timing of keywords and the relationship network diagram of cluster analysis. The size of the dot indicates the frequency of occurrence, and the colour of the dot represents the cluster and the time of occurrence. The curve describes the interrelationship. The disease formation, target, and...
regulation mode can be roughly acquired through cluster analysis. It can be seen from the time sequence that lncRNAs, AAAs, and circRNAs are newly emerging keywords in recent years. Figure 3(b) is a timeline view of analyzing keywords from 1996 to 2020.

The classification method is to name the index terms in the search keywords. We can get ten clusters with an order from #0 to #10. The smaller the number # is, the more keywords the cluster contains. Each cluster is composed of multiple closely related words. The largest cluster is "aortic aneurysm" (#0), followed by "abdominal aortic aneurysm formation" (#1). A module clustering value (Q value) greater than 3 generally means a significant clustering structure. In the figure, modularity Q = 0.684. Figure 4(a) is a network diagram obtained based on the number of papers published and cooperative relationships in each country, showing the interconnection between countries. The heat map in Figure 4(b) presents the number of national papers published on the world map.

4. Verified circRNAs in AAAs

Data on circRNAs in aneurysms are scarce, but abnormal expression of circRNAs in aneurysms has been observed in emerging studies. However, the functional role(s) of these circRNAs in AAA development in animal models and their therapeutic potential are yet to be elucidated.

4.1. circRNA Microarray Profiling of Human AAAs. Zhou et al. from China observed differential expression of circRNAs in AAA samples and controls, so they subsequently conducted high-throughput sequencing to determine the circRNA expression patterns in four pairs of aortic samples, including four consecutive AAA cases undergoing open surgery and four brain-dead heart-beating organ samples [83]. Finally, a total of 411 differentially expressed circRNAs were detected in AAA samples, including 145 upregulated circRNAs and 266 downregulated circRNAs. Six abnormally expressed circRNAs, namely, hsa_circ_0070382 (AFF1), hsa_circ_0060063 (UQCC1), hsa_circ_0028198 (ANAPC7), hsa_circ_0027446 (HMGA2), hsa_circ_0002168 (TMEM189), and hsa_circ_0005360 (LDLR), were then screened out for RT-PCR analysis. Among the six circRNAs, 2 were upregulated, and 4 were downregulated. According to a population-based genome-wide association study, LDLR is the parental gene of hsa_circ_0005360, and its variant is related to AAAs [84]. Additionally, LDLR-deficient mice infused with Ang II infusion are extensively used as AAA animal models [85–87]. Given the alternative transcription of hsa_circ_0005360 in the LDLR exons, hsa_circ_0005360 possibly plays a vital role in AAA development.
part in the pathogenic mechanism of AAAs. In the meantime, the interaction networks of circRNAs/miRNAs were also predicted by computational analysis (Table 1). As indicated in the interaction networks of circRNAs/miRNAs, hsa_circ_0002168 and hsa_circ_0005360 contain one binding site for miR-15a and miR-181b, respectively. It is evident that overexpressed miR-181b in AAA patients downregulates elastin and the MMP-3 tissue inhibitor, thereby promoting AAA development [88]. As for miR-15a, it negatively regulates CDKN2B expression and thereby promotes VSMC apoptosis, possibly resulting in AAA pathogenesis [89]. Nonetheless, the hsa_circ_0002168/miR-15a and hsa_circ_0005360/miR-181b axes should be further validated in AAAs by more studies (Figure 5).

4.2. circRNA Microarray Profiling of Mouse AAAs Induced by Ang II. Wang et al. collected two samples from each of the AAA and control groups and analyzed the circRNA expression profiles. The AAA samples of C57BL/6j male mice were treated with Ang II and 3,4-benzopyrene (BAP), and the circRNA expression in these AAA samples was compared with that in the control group [90]. The qRT-PCR results showed

---

**Figure 2:** Statistics of AAA and ncRNA papers published. (a) The relationship between “circRNA, ncRNA, and abdominal aortic aneurysm” and “published volume and year of publication” (b) The relationship between the number of “circRNA, miRNA, mRNA” and “the year of publication.”
that 271 circRNAs showed upregulation while 142 circRNAs were downregulated (Table 1). After predicting the related regulatory pathway, the authors mapped the downregulated mRNAs into 7 pathways, including apoptosis. It should be noted that apoptosis is well-received as a critical biological process of VSMCs in AAAs, and VSMC apoptosis can also be detected in AAAs induced by Bap/Ang II. In line with the above results, Wang et al. examined the competitive endogenous RNA (ceRNA) mechanism related to certain apoptotic circRNAs. For instance, two miRNAs (mmu-let-7a-2-3p and mmu-miR-199a-3p) of differentially expressed mmu_circRNA_001265 and their response elements were
Figure 4: The analysis of total country output based on ncRNA research. (a) Network map of countries/regions engaged in ncRNA research (b) World map of total country output engaged in ncRNA research.
### Table 1: Verified circRNAs in AAAs.

| circRNA       | Gene symbol | Regulation | Pathway                                                                 | Cell type                                                                 | Function                                                                 | Ref  |
|---------------|-------------|------------|------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|------|
| hsa_circ_002168 | TMEM189     | Down       | hsa-miR-298, hsa-miR-503b-5p, hsa-miR-296b-3p, hsa-miR-612, hsa-miR-15a-3p, hsa-miR-15a, hsa-miR-670-3p | circRNA microarray analysis of AAA tissue and healthy aorta tissue         | N/A                                                                        | 83   |
| hsa_circ_005360 | LDLR         | Down       | hsa-miR-181b, hsa-miR-671-5p, hsa-miR-616-3p, hsa-miR-135b-3p, hsa-miR-186-5p | circRNA microarray analysis of AAA tissue and healthy aorta tissue         | N/A                                                                        | 83   |
| hsa_circ_0060063 | UQCC1       | Up         | hsa-miR-223-3p, hsa-miR-541-5p, hsa-miR-145b-3p, hsa-miR-137, hsa-miR-432-3p | circRNA microarray analysis of AAA tissue and healthy aorta tissue         | N/A                                                                        | 83   |
| Homo sapiens  |             |            |                                                                        |                                                                            |                                                                            |      |
| hsa_circ_0070382 | AFF1        | Up         | hsa-miR-890, hsa-miR-135b-3p, hsa-miR-24-3p, hsa-miR-6882-3p, hsa-miR-129-5p | circRNA microarray analysis of AAA tissue and healthy aorta tissue         | N/A                                                                        | 83   |
| hsa_circ_0027446 | HMGA2       | Up         | hsa-miR-331-3p, hsa-miR-1236-3p, hsa-miR-3925-3p, hsa-miR-493-3p | circRNA microarray analysis of AAA tissue and healthy aorta tissue         | N/A                                                                        | 83   |
| hsa_circ_0028198 | ANAPC7      | Up         | hsa-miR-153-5p, hsa-miR-7-5p, hsa-miR-205-3p | circRNA microarray analysis of AAA tissue and healthy aorta tissue | Expression of ASPH and PDE3B may be regulated by hsa_circ_0028198, hsa-miRNA-19a | 83   |
| hsa_circ_CCDC66 | CCDC66      | Up         | *hsa-miR-342-3p                                                                 | SMC                                                                       | VSMC growth and apoptosis                                                 | 91   |
| hsa_circ_CBFB  | CBFB        | Up         | *hsa-miR-28-5p/GRIA4/LYPD3 axis                                                                 | VSMC                                                                      | VSMC apoptosis and growth                                                 | 92   |
| hsa_circ_CDR1as | CDR1as      | Down       | *hsa-miRNA-7/CKAP4 axis                                                                 | AAA and VSMC                                                              | VSMC apoptosis and growth                                                 | 94   |
| hsa_circ_000595 | N/A         | Up         | *hsa-miRNA-19a                                                                 |                                                                            |                                                                            | 95   |
| circRNA   | Gene symbol | Regulation | Pathway                                                                 | Cell type                                      | Function                                      | Ref |
|-----------|-------------|------------|-------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----|
| mmu_circ_29892 | Pros1   | Up         | mmu-miR-212-5p, mmu-miR-7033-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
| mmu_circ_45403 | Wdr44    | Up         | mmu-miR-7235-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
| mmu_circ_40388 | Kdm3a   | Up         | mmu-miR-7235-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
| mmu_circ_27294 | Ccdc66  | Up         | mmu-miR-7235-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
| Mus musculus mmu_circ_001265 | Chordc1  | Down       | mmu-miR-7235-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
| mmu_circ_018331 | Hivep1   | Down       | mmu-miR-7235-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
| mmu_circ_40599 | Frm4d4b  | Down       | mmu-miR-7235-3p, mmu-miR-23b-3p, mmu-miR-6947-3p, mmu-miR-541-5p, mmu-miR-7235-3p, mmu-miR-141-5p, mmu-miR-7026-3p, mmu-miR-301a-5p, mmu-miR-92a-2-5p, mmu-miR-6922-3p, mmu-miR-3078-3p, mmu-let-7c-1-3p, mmu-miR-500-5p, mmu-miR-19b-2-5p, mmu-miR-7092-3p, mmu-miR-6946-3p | circRNA microarray analysis of Ang II-induced in mice | N/A                                           | 90  |
predicted. Another study suggests that lncRNA H19 causes aneurysms partially through endogenously competing with let-7a miRNA for inducing transcription of the target gene (IL-6) [55].

4.3. Examples of Several circRNA-Guided Signaling Pathways in AAAs

4.3.1. circRNA CCDC66. To prove the role of circRNA CCDC66 in the pathogenesis of AAAs and identify its corresponding pathway, Yang et al. carried out a study and found that circCCDC66 played a role in the proliferation of VSMCs [91]. Through further investigation, they discovered that circCCDC66 promoted the expression of CCDC66, and CCDC66 suppression had the same effect as circCCDC66 deletion on the development and apoptosis of VSMCs. Moreover, the RNA pull-down test results suggested that the content of circCCDC66 and CCDC66 was the highest in the miR-342-3p group, indicating that circCCDC66 influenced CCDC66 through miR-342-3p. Taken together, it is concluded that overexpression of CCDC66 causes AAAs through the circCCDC66/miR-342-3p/CCDC66 pathway (Figure 5).

4.3.2. circRNA CBFB. Findings of this study reveal that miR-28-5p, circCBFB, GRIA4, and LYPD3 are involved in AAAs. circCBFB serves as the miR-28-5p sponge, capable of regulating the proliferation and apoptosis of VSMCs in a LYPD3/GRIA4-dependent manner [92]. With regard to the relationship between circCBFB and AAAs, it is established previously that the expression of miR-28-5p increases in AAAs. As reported by Yue et al., miR-28-5p promotes VSMC apoptosis and suppresses their proliferation, thereby contributing to AAA occurrence [92]. Moreover, bioinformatic analysis verifies LYPD3 and GRIA4 as the potential miR-28-5p target genes. The mechanical experiments of this study suggest that miR-28-5p targets GRIA4 and LYPD3 and restrains their expression in VSMCs. Additionally, functional analysis proves that GRIA4 and LYPD3 deficiency promotes the apoptosis of VSMCs. More innovative strategies are required to identify the role of the circCBFB molecule in AAAs. Based on the above analysis, it can be concluded that circCBFB induces cell apoptosis and AAA formation through the circCBFB/miR-28-5p/GRIA4/LYPD3 pathway (Figure 5).

4.3.3. circRNA CDR1. There are over 70 miR-7 binding sites in the cerebellar degeneration-related protein 1 antisense RNA (CDR1as), and these sites regulate the effect of CDR1as on the target gene expression [93]. According to recent research, the expression levels of CDR1as and CKAP4 (the estimated miR-7 target) are lower in AAA cases than those in normal controls [94]. Zhao et al. suggested that the CDR1as/miR-7/CKAP4 axis plays a role in VSMCs of AAA cases and that CDR1as upregulation may curb the expression of miR-7. What is more, CDR1as upregulation enhances the CKAP4 level, promotes VSMC proliferation, and suppresses VSMC apoptosis, thereby resulting in VSMC remodeling along with AAA progression. Such novel mechanism offers insights into AAA treatment approaches (Figure 5).

4.3.4. Hsa_circ_000595. Through screening circRNAs in tissue specimens from AAA patients, Zheng et al. observed increased expression of hsa-circ-000595 in diseased specimens [95]. A similar pattern was found in hypoxic aortic SMCs, and the knockdown of hsa-circ-000595 reduced SMC apoptosis. Besides, they also found that miR-19a might serve as a potential downstream target of hsa-circ-000595. Hsa-circ-000595 on the chromosome 14 can modulate the

---

**Figure 5:** Several circRNA mediated signaling pathways in AAA. In human and mouse abdominal aortic aneurysms, the plan view of the abdominal aorta and several circRNA mediated signal pathways.
miR-19a activity and acts on AAAs through suppressing cell apoptosis [95].

5. Potential circRNAs in AAAs

At present, the pathogenic mechanism of AAAs is mainly explored through studying aortic tissue from AAA patients undergoing open surgery. Several subtypes of vascular cells (including SMCs, ECs, and adventitial cells) are involved in AAA genesis [20] (Figure 6).

Disordered ECs may induce adventitia and media inflammation [96]. The chronic inflammatory reaction induced by T cells [97] triggers MMP- and macrophage-mediated proteolytic remodeling, finally weakening the ECM structure. Such process is related to elastic fiber loss, collagen fiber structural alterations, and new vessel formation (angiogenesis). Generally speaking, inflammation is a vital contributor to aneurysm occurrence and development. Infiltinating leukocytes and macrophages are the main proteinase sources. The transformation of VSMCs from the contractile/differentiated phenotype to the synthetic/dedifferentiated phenotype correlates with AAA occurrence [98]. VSMCs constitute the principal part of the aortic wall. They proliferate and dedifferentiate to trigger different signaling cascades, which in turn stimulate proliferation, dedifferentiation, apoptosis, and migration of VSMCs.

However, these physiological characteristics facilitate the formation of vulnerable atherosclerotic plaques in the aneurysmal wall, which illustrates that AS is a vital risk factor for AAAs [99]. Age, smoking, and the genetic background are common and the most potent factors leading to these two disorders [100]. Therefore, these processes are at least partly regulated by circRNAs. We aim to speculate the potential relationship of circRNAs with ECs and SMCs in AAAs.

5.1. circRNAs and ECs in AAAs

Numerous pathophysiological stimuli can result in EC disorders in AAAs, including hypoxia [101], advanced glycation end products (AGEs) [102], reactive oxygen species (ROS) [103], oxidized low-density lipoproteins (ox-LDLs) [104], and proinflammatory cytokines [105] (Table 2).

A study has revealed the potential role of hypoxia-mediated new vessel formation in the pathogenic mechanism of AAAs [106]. Dang et al. examined the expression patterns of circRNAs in hypoxia-stressed human umbilical vein endothelial cells (HUVECs) and detected the notable upregulation of hsa_circ_0010729. They also found that hsa_circ_0010729 deletion inhibited cell migration and proliferation, but promoted cell apoptosis through targeting the miR-186/HIF-1α axis [107]. Recent evidence suggests that the hypoxia-induced circAFF1 can lead to disordered vascular ECs through triggering SAV1/YAP1. From the mechanical perspective, the circAFF1/miR-516b/SAV1/YAP1 axis partially contributes to vascular endothelium dysfunction, and it may be used as an indicator of hypoxia injury-induced vascular diseases [108]. Furthermore, significantly upregulated cZNF609 was observed by Liu et al. in HUVECs exposed to hypoxia and HG environments. As claimed by some researchers, the silencing of cZNF609 prevents EC apoptosis but stimulates tube formation and migration of ECs, demonstrating that cZNF609 can promote the apoptosis of stress-challenged ECs. Mechanically, cZNF609 acts as a ceRNA, which upregulates the expression of myocyte enhancer factor 2A (MEF2A) through separating and suppressing miR-615-
According to the above research results, circRNAs regulate EC phenotypes in the hypoxic environment. High glucose (HG) affects the formation and development of AAAs [110, 111] through enhancing ROS generation [112] and AGE synthesis. In HG-stimulated EC models, circRNAs regulate the phenotypes of ECs. circBPTF is under tight regulation within the HG-challenged HUVECs, and circBPTF deletion prevents the HG-mediated OS and inflammatory injuries through regulating the miR-384/LIN28B axis [113]. In addition, the expression of hsa_circ_0068087 also increases within the HG-challenged HUVECs, and hsa_circ_0068087 deletion attenuates the inflammation and angiogenic disorder in HG-challenged HUVECs through pathways like pyrin domain-containing protein 3 (NLRP3) inflammasome, LRR, and toll-like receptor 4 (TLR4)/NF-κB/NLRP3 [114]. Research has found circ_0003204 is mostly located in the cytoplasm of HAECs, and its expression increases in ox-LDL-challenged HAECs. Overexpressed circ_0003204 restrains the proliferation, tube formation, and migration of ox-LDL-challenged HAECs. Mechanically, circ_0003204 acts as the miR-370 sponge, which increases the protein levels of transforming growth factor (TGF) βR2 and the corresponding downstream phosph-SMAD3 [115]. A recent study focusing on circ_0003204 underlines the vital role of hsa_circ_0003204 in HUVEC proliferation and new vessel formation. Besides, hsa_circ_0003204 deletion evidently downregulates the expression of E-cadherin and upregulates the expression of vimentin and N-cadherin in oxLDL-challenged ECs [122]. Wang et al. have noticed that circ_0124644 alleviates the endothelial injuries in ox-LDL-challenged HUVECs through the miR-149-5p/PAPP-A axis [123]. It is also shown that circ_0003645 deletion mitigates the apoptosis and inflammation in oxLDL-challenged ECs [124].

OxLDLs affect the O2•− concentration in several ways. Increasing the O2•− concentration causes the NOS to dephosphorize to produce O2•−-[117, 118], inhibits dismutase activities, and curbs O2•− reduction to H2O2. OxLDLs promote inflammatory cell infiltration into the aortic wall through enhancing the activities of MMP2 [119], chemokines, and adhesion particles [120]. Research has found circ_0003204 is mostly located in the cytoplasm of HAECs, and its expression increases in ox-LDL-challenged HUVECs. Overexpressed circ_0003204 restrains the proliferation, tube formation, and migration of ox-LDL-challenged HUVECs. Mechanically, circ_0003204 acts as the miR-370 sponge, which increases the protein levels of transforming growth factor (TGF) βR2 and the corresponding downstream phosph-SMAD3 [121]. A recent study focusing on circ_0003204 underlines the vital role of hsa_circ_0003204 in HUVEC proliferation and new vessel formation. Besides, hsa_circ_0003204 deletion evidently downregulates the expression of E-cadherin and upregulates the expression of vimentin and N-cadherin in oxLDL-challenged HUVECs [122]. Wang et al. have noticed that circ_0124644 alleviates the endothelial injuries in ox-LDL-challenged HUVECs through the miR-149-5p/PAPP-A axis [123]. It is also shown that circ_0003645 deletion mitigates the apoptosis and inflammation in oxLDL-challenged ECs [124].

5.2. circRNAs and SMCs in AAAs. VSMC phenotypic transformation within AAAs is ascribed to pathophysiological
incentives as diverse as ox-LDLs, Ang II, proinflammatory factors, and hyperglycemia (Table 3).

The circ_0010283 level in ox LDL-challenged VSMCs is remarkably higher than that in control VSMCs. The circ_0010283 target is miR-370-3p, which targets HMGB1. As a result, circ_0010283 modulates the level of HMGB1 through miR-370-3p/HMGB1 [125]. The high serum expression of circ_0010283 in AS cases and human VSMCs treated with ox-LDLs is confirmed by Feng et al., who report that circ_0010283 modulates the PAPPA level through regulating miR-133a-3p/PAPPA [126]. Similarly, the abnormal expression of circCHFR is also detected in ox-LDL-treated VSMCs. In addition, the circCHFR/miR-370/FOXO1/Cyclin D1 axis is found to play a key role in SMCs, which increases our knowledge of circRNAs in SMCs [127]. As revealed by a study, circCHFR is upregulated in serum of atherosclerosis patients and ox-LDL-stimulated VSMCs. circCHFR controls cell growth, migration, and inflammation via regulating the expression of Wnt3 as a ceRNA of miR-214 in ox-LDL-treated VSMCs [128]. Correspondingly, circ_0029589 deletion suppresses the proliferation, invasion, and migration of ox-LDL-challenged VSMCs through modulating STIM1 and miR-214-3p [130].

Ang II has been suggested to enhance VSMC proliferation in the process of vascular remodeling and play a vital part in AAA formation. According to circRNA microarray analysis, mmu-circRNA-42742 is conspicuously downregulated in Ang II-treated mouse aortic smooth muscle cells (MASMCs). The parental gene of mmu-circRNA-42742 is NRG-1, which modulates vascular remodeling via the ErbB signal transduction pathway. Besides, the circNRG-1/miR-193b-5p/NRG-1 axis can be potentially used as the Ang II target for inhibiting VSMC apoptosis and facilitating vascular remodeling [131].

The analysis of circRNA expression in the HG-induced VSMCs shows that circWDR77 is upregulated. The predicted results are miR-124 and fibroblast growth factor 2 (FGF-2), whose interaction is verified by the RNA pull-down experiment and luciferase reporter gene assay. More importantly, Wang et al. found that exosomes from HG-induced HUVECs caused VSMC senescence via the circRNA-0077930/miR-622-Kras ceRNA axis, while exosomes with circRNA-0077930 depletion had no implications for VSMC senescence [132].

### Table 3: CircRNAs causing VSMC disorder in AAAs.

| circRNA   | Cell type     | Inducing factor | Expression | Pathway                          | Function                                           | Ref   |
|-----------|---------------|-----------------|------------|----------------------------------|----------------------------------------------------|-------|
| circ_0010283 | VSMCs         | ox-LDL          | Up         | miR-370-3p/HMGB1                 | Promoted VSMC viability and migration, and proliferating cell nuclear antigen | 125   |
|           | HVSMCs        | ox-LDL          | Up         | miR-133a-3p/PAPPA                | Promoted VSMC proliferation, migration and invasion | 126   |
|           | VSMCs         | ox-LDL          | Up         | miR-370/FOXO1/Cyclin D1          | Promoted proliferation and migration ability of VSMCs | 127   |
|           | VSMCs         | ox-LDL          | Up         | miR-214-3p/Wnt3/β-catenin        | Promoted cell growth, migration, and inflammation | 128   |
|           | VSMCs         | ox-LDL          | Up         | miR-424-5p/IGF2                  | Promoted proliferation, migration, and invasion    | 129   |
|           | VSMCs         | ox-LDL          | Up         | miR-214-3p and STIM1             | Promoted proliferation, migration, and invasion    | 130   |
|           | circNRG-1     | MASMCs          | Down       | miR-193b-5p/NRG-1                | Promoted apoptosis                                 | 131   |
|           | CircWDR77     | VSMCs/MASMCs    | HG Up       | miR-124/FGF-2                   | Promoted migration and proliferation                |       |
|           | CircWDR77     | HUVEC-Exosomes  | HG          | miR-622-Kras                    | Induce cellular senescence in VSMCs                | 132   |
|           | CircWDR77     | HUVECs          | LPS Down    | miR-107/JAK/STAT                 | Promoted the proliferation and invasion            | 133   |
|           | CircWDR77     | HUVECs          | TNF-α Up    | miR-132/212/SIRT1                | Inhibited inflammation                             | 134   |
|           | CircDHC24     | HA-VSMCs        | PDGF-BB Down| miR-149-5p/MMP9                  | Promoted proliferation, migration, and phenotypic switch | 135   |
|           | CircSATB2     | Proliferative VSMCs | N/A Up   | miR-939/STM1                    | Promoted migration, proliferation; inhibited apoptosis | 136   |
|           | CircRUSC2     | Proliferative VSMCs | N/A Up   | miR-661/SYK                     | Promoted migration, proliferation; inhibited apoptosis | 137   |
|           | CircACTA2     | HASMCs          | N/A Up      | NRG-1/circACTA2/miR-548f-5p     | Promoted contraction                               |       |

---

Oxidative Medicine and Cellular Longevity
Furthermore, Zheng et al. noticed the upregulation of hsa_circ_000595 in the hypoxia-induced human aortic smooth muscle cells (HASMCs). They concluded that hsa_circ_000595 silencing acted as the miR-19a sponge to suppress cell apoptosis [95].

AAAs are a type of chronic inflammatory disorders, so the in vitro AS model can be constructed by inflammatory stimulation. circRNA-0044073 is upregulated in the LPS-treated human umbilical vein smooth muscle cells (HUVECs) but downregulated in LPS-treated HUVecs. Further exploration indicates that circRNA-0044073 overexpression evidently promotes HUVECs and HUVEC proliferation and invasion through the miR-107/Janus kinase (JAK)/STAT signal transduction pathway [133]. As demonstrated by Kong et al., the circ-Sirt1 expression level is distinctly downregulated in TNF-α-treated VSMCs, and circ-Sirt1 overexpression impedes the NF-κB p65 nuclear translocation and lowers the levels of adhesion molecules and proinflammatory cytokines (particularly VCAM-1, MCP-1, and ICAM-1) [134]. Moreover, they have also discovered that circ-Sirt1 prevents the transcription and acetylation of NF-κB p65 induced by TNF-α through reversing the inhibition effect of miR-132/212 on SIRT1. The study results of Kong et al. suggest that circ-Sirt1 may mitigate the NF-κB p65-induced inflammation via direct and indirect approaches. After treating the human aortic vascular smooth muscle cells (HA-VSMCs) with PDGF-BB, Peng et al. found that circDHCR24 deletion served as the miR-149-5p sponge and diminished the cell proliferation [135].

Additionally, the levels of circ_RUSC2 and circ_SATB2 decrease within the proliferating VSMCs. It is disclosed by Mao et al. that circ-SATB2 promotes STIM1, which can be explained by the role of miR-939 in proliferative VSMCs. Mechanically, circ-SATB2 overexpression inhibits the expression of contractile VSMC marker SM22a, while miR-939 promotes its expression, indicating an association between circ-SATB2 and VSMC phenotypic differentiation [136]. circ_RUSC2 is reported to enhance the proliferation, migration, and phenotypic regulation of VSMCs, but suppress their apoptosis through the miR-661/spleen-associated tyrosine kinase (SYK) signal transduction pathway [137].

5.3. circRNAs and Macrophages in AAAs. CircRNAs are proven to be essential for the modulation of macrophages. Studies have shown that in LPS-induced macrophages Raw264.7, circ_1639 promotes the proinflammatory response in Raw264.7 cells. The study of Lu et al. demonstrates that circ_1639 expression is tremendously upregulated in LPS-treated Raw264.7 cells. The level of p-P65 increases in circ_1639 mock-transfected cells, but declines in cells transfected with circ_1639 inhibitor plasmid. Therefore, circ_1639 regulates inflammatory response through the NF-κB signaling pathway. When Raw264.7 cells are transfected with the circ_1639 mimic, the level of miR-122 gene is significantly reduced, while the expression of its target gene TNFRSF13C increases. Hence, it can be concluded that in Raw264.7 cells, circ_1639 affects the inflammatory response through the miR-122/TNFRSF13C regulatory axis [138].

In Raw264.7 macrophages stimulated by the calcitonin gene-related peptide (CGRP), increased expression of mmu_circRNA_007893 and decreased expression of miR-485-5p are detected. The coimmunoprecipitation reaction further confirms the interaction among mmu_circRNA_007893, miR-485-5p, and IL-6. In Raw264.7 cells, the mmu_circRNA_007893/miR-485-5p/IL-6 regulatory pathway regulates the inflammatory response by controlling the expression of the cytokine IL-6 and ultimately affects the cell function [139].

The above results indicate that the function of macrophages can be affected by the expression level of the circRNA regulatory axis, such as the proinflammatory cytokines (e.g., TNF-α and IL-6) and anti-inflammatory cytokines. There is a lot of evidence that circRNAs play a vital role in macrophages, and it will assist with further research on the diseases caused by macrophages and circRNAs.

5.4. circRNAs in Aortic Dissection Tissue and Intracranial Aneurysms

5.4.1. circRNAs in Aortic Dissection Tissue. In a previous study, a targeted circRNA array was applied to exploring differentially expressed circRNAs in tissue specimens from thoracic aortic dissection (TAA) patients undergoing surgery [140]. As observed from the qRT-PCR assays, the expression levels of hsa_circRNA_102771, hsa_circRNA_002271, hsa_circRNA_101238, hsa_circRNA_104349, hsa_circRNA_104634, COL6A3, and COL1A1 increase, while the expression of hsa_circRNA_005525, hsa_circRNA_102683, hsa_circRNA_103458, and FLNA is downregulated. Meanwhile, circRNA_101238 is found to not only be deregulated with the disease but also potentially affect miR-320a expression and MMP9 levels. Moreover, the expression of both hsa_circRNA_104634 interacting with hsa-miR-145-3p and hsa_circRNA_104349 interacting with hsa-miR-26a-3p is upregulated, which promotes the apoptosis or phenotypic transformation of SMCs [141]. According to another study, hsa_circRNA_104033 and hsa_circRNA_102683 can suppress hsa-miR-195-3p and hsa-miR-29b-1-5p levels, respectively, thereby aggravating aortic wall apoptosis and ECM degradation and promoting collagen remodeling [142]. Thus, those differentially expressed circRNAs discovered possibly contribute to TAD occurrence through several biological processes [140].

Through carrying out RNA-Seq on the affected ascending aortic samples from patients with acute Stanford type A aortic dissection (AAAD), Tian et al. have identified 506 evidently differentially expressed circRNAs [143]. Besides, the levels of ten circRNAs with the most significant differential expression are either increased or decreased by 2-5 folds. Specifically, circUBA2, circARHGAP26, circIQGAP1, circCHSY1, circMED13, circMBNL1, circMYH110, and circRAB7A are upregulated, while circFAM120B and circCEP70 are downregulated. Moreover, the analysis results of the circRNA-miRNA-mRNA network disclose the regulatory effect of circMARK3 on the expression of Fgr, which is a kind of tyrosine-protein kinase. The findings of Tian et al. demonstrate the clinical significance of the circMARK3.
miR-1273-Fgr interaction and that the combined use of circRNAs and additional biomarkers can improve the diagnostic accuracy.

5.4.2. circRNAs in Peripheral Blood of Intracranial Aneurysms. One recent effort identifies the hsa_circ_0021001 in peripheral blood of patients with intracranial aneurysms, but its potential contribution to aneurysmal expansion is not expounded [144]. Hsa_circ_0021001 has an area under the receiver operating characteristic ROC curve (AUC) of 0.87, demonstrating its effectiveness in IA diagnosis.

In a study, the circRNA sequencing on IA patients recognizes two novel circRNAs in the peripheral blood samples from IA cases, and their expression in peripheral blood of normal subjects are also analyzed. The results suggest that hsa_circ_0008433 and hsa_circ_0072309 are new and critical circRNAs associated with IAs. This study may provide novel prognostic biomarkers and therapeutic targets for IAs [145].

5.4.3. Hsa_circRNA_0020397 in Intracranial Aneurysm Tissue. Wang et al. acquired arterial wall tissue samples from the aneurysm site in 12 cases and discovered that circRNA_0020397 was downregulated in IAs. The decreased circRNA_0020397 expression possibly suppressed the proliferation of VSMCs through upregulating miR-138 levels and downregulating KDR levels [146].

6. Summary and Perspectives

AAAs are one of the major causes leading to cardiovascular death among the senile male population, and their etiology is complex, including apoptosis of SMCs and inflammatory reaction. It is of urgent need to develop new pharmacological approaches or gene therapy strategies for delaying aneurysm development or lowering the risk of acute rupture. Over the last few decades, ncRNAs are increasingly identified as critical regulators for AAA occurrence and development. Hence, it is necessary to identify abnormally expressed ncRNAs and validate them in relevant human AAA tissue and animal models, so as to better explore the pathophysiological mechanisms related to AAA genesis and development.

Different from traditional linear RNAs, circRNAs are a novel class of RNAs with a closed loop structure that can be detected in the eukaryotic genome. Besides, they show higher stability and greater resistance to RNase degradation, so they are widely used as biomarkers. However, there is no evidence that peripheral blood circRNAs are effective biomarkers for the diagnosis of AAAs, and further investigation is required to confirm the relationship between circulating circRNAs and AAAs.

It is reported that circRNAs function as the molecular “sponge,” capable of regulating transcription and posttranscriptional gene expression by binding to and blocking microRNA regulatory factors. The regulatory pathway of circRNAs is circRNA-miRNA-mRNA. A circRNA specifically binds to an miRNA and inhibits its expression, thereby regulating the expression level of the template RNA.

In this paper, the relationship between circRNAs and AAAs is briefly described. It is proved that several circRNAs affect the formation of AAAs by regulating the proliferation and apoptosis of VSMCs. Meanwhile, the changes of aneurysmal wall cells (e.g., immune cells and ECs) in the AAA development process can be well analyzed based on the circRNAs extracted from these cells. When the differential expression of these circRNAs is verified, the molecular mechanisms of circRNAs in regulating AAA occurrence are investigated both in vitro and in vivo. Meanwhile, the mechanism of action is further elaborated.

Because of the above-mentioned characteristics, circRNAs have been listed as a biomarker and therapeutic target for AAAs. The expression and regulation of circRNAs will directly affect the development of AAAs.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

All authors read and approved the final manuscript.

Acknowledgments

We thank professional editors at STS (Changsha Shiyu Translation Service Co., Ltd.) for editing the English text of a draft of the manuscript. This work was supported by the Fundamental Research Funds for the Central Universities (grant number: DUT19RC(3)076), the National Natural Science Foundation of China (grant number: 81600370), and the China Postdoctoral Science Foundation (grant number: 2018M640270) for Yanshuo Han. This work was supported by the National Natural Science Foundation of China (grant: 81970402) for Jian Zhang.

References

[1] W. S. Aronow, “Peripheral arterial disease and abdominal aortic aneurysm in elderly people,” Minerva Medica, vol. 102, no. 6, pp. 483–500, 2011.
[2] US Preventive Services Task Force, D. K. Owens, K. W. Davidson et al., “Screening for abdominal aortic aneurysm: US Preventive Services Task Force recommendation statement,” JAMA, vol. 322, no. 22, pp. 2211–2218, 2019.
[3] J. S. Lindholt, “Abdominal aortic aneurysms,” Danish Medical Bulletin, vol. 57, no. 12, p. B4219, 2010.
[4] F. A. Hellenthal, W. A. Buurman, W. K. Wodzig, and G. W. Schurink, “Biomarkers of AAA progression. Part 1: extracellular matrix degeneration,” Nature Reviews. Cardiology, vol. 6, no. 7, pp. 464–474, 2009.
[5] F. A. Hellenthal, W. A. Buurman, W. K. Wodzig, and G. W. Schurink, “Biomarkers of abdominal aortic aneurysm.
progression. Part 2: inflammation,” Nature Reviews. Cardiology, vol. 6, no. 8, pp. 543–552, 2009.

[6] R. W. Thompson, P. J. Geraghty, and J. K. Lee, “Abdominal aortic aneurysms: basic mechanisms and clinical implications,” Current Problems in Surgery, vol. 39, no. 2, pp. 110–230, 2002.

[7] F. L. Moll, J. T. Powell, G. Fraedrich et al., “Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery,” European Journal of Vascular and Endovascular Surgery, vol. 41, Suppl 1, pp. S1–S58, 2011.

[8] A. Conway, A. H. Malkawi, R. J. Hinchcliffe et al., “First-year results of a national abdominal aortic aneurysm screening programme in a single centre,” The British Journal of Surgery, vol. 99, no. 1, pp. 73–77, 2012.

[9] H. A. Ashton, M. J. Buxton, N. E. Day et al., “The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial,” Lancet, vol. 360, no. 9345, pp. 1531–1539, 2002.

[10] M. Zarrouk, J. Holst, M. Malina et al., “The importance of socioeconomic factors for compliance and outcome at screening for abdominal aortic aneurysm in 65-year-old men,” Journal of Vascular Surgery, vol. 58, no. 1, pp. 50–55, 2013.

[11] M. Gawenda and J. Brunkwall, “Ruptured abdominal aortic aneurysm: the state of play,” Deutsches Ärzteblatt International, vol. 109, no. 43, pp. 727–732, 2012.

[12] M. Johansson, P. H. Zahl, V. Siersma, K. J. Jørgensen, B. Marklund, and J. Brodersen, “Benefits and harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort study,” Lancet, vol. 391, no. 10138, pp. 2441–2447, 2018.

[13] H. H. Eckstein, T. Bruckner, P. Heider et al., “The relationship between volume and outcome following elective open repair of abdominal aortic aneurysms (AAA) in 131 German hospitals,” European Journal of Vascular and Endovascular Surgery, vol. 34, no. 3, pp. 260–266, 2007.

[14] R. M. Greenhalgh and E. V. The, “Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1),” Lancet, vol. 364, no. 9437, pp. 843–848, 2004.

[15] Y. Han, S. Zhang, J. Zhang, C. Ji, and H. H. Eckstein, “Outcomes of endovascular abdominal aortic aneurysm repair in octogenarians: meta-analysis and systematic review,” European Journal of Vascular and Endovascular Surgery, vol. 54, no. 4, pp. 454–463, 2017.

[16] M. Trenner, B. Haller, M. Sterck, B. Reutersberg, M. A. Kallmayer, and H. H. Eckstein, “Trends in patient safety of intact abdominal aortic aneurysm repair: German registry data on 36,594 procedures,” European Journal of Vascular and Endovascular Surgery, vol. 53, no. 5, pp. 641–647, 2017.

[17] J. Golledge, “Abdominal aortic aneurysm: update on pathogenesis and medical treatments,” Nature Reviews. Cardiology, vol. 16, no. 4, pp. 225–242, 2019.

[18] Y. D. Wang, Z. J. Liu, J. Ren, and M. X. Xiang, “Pharmacological therapy of abdominal aortic aneurysm: an update,” Current Vascular Pharmacology, vol. 16, no. 2, pp. 114–124, 2018.

[19] A. Giraud, L. Zeboudj, M. Vandestienne et al., “Gingival fibroblasts protect against experimental abdominal aortic aneurysm development and rupture through tissue inhibitor of metalloproteinase-1 production,” Cardiovascular Research, vol. 113, no. 11, pp. 1364–1375, 2017.

[20] K. Riches, E. Clark, R. J. Helliwell et al., “Progressive development of aberrant smooth muscle cell phenotype in abdominal aortic aneurysm disease,” Journal of Vascular Research, vol. 55, no. 1, pp. 35–46, 2018.

[21] H. Lu, J. Sun, W. Liang et al., “Cycloheximide prevents abdominal aortic aneurysm via activation of vascular smooth muscle cell TFE2,” Circulation, vol. 142, no. 5, pp. 483–498, 2020.

[22] N. Bogunovic, J. P. Meekel, D. Micha, J. D. Blankensteijn, P. L. Hordijk, and K. K. Yeung, “Impaired smooth muscle cell contractility as a novel concept of abdominal aortic aneurysm pathophysiology,” Scientific Reports, vol. 9, no. 1, p. 6837, 2019.

[23] G. M. Longo, S. J. Buda, N. Fiotta et al., “MMP-12 has a role in abdominal aortic aneurysms in mice,” Surgery, vol. 137, no. 4, pp. 457–462, 2005.

[24] W. W. Lu, L. X. Jia, X. Q. Ni et al., “Intermedin-1-3 attenuates abdominal aortic aneurysm by inhibiting oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 11, pp. 2176–2190, 2016.

[25] E. J. Ryer, K. E. Ronning, R. Erdman et al., “The potential role of DNA methylation in abdominal aortic aneurysms,” International Journal of Molecular Sciences, vol. 16, no. 5, pp. 11259–11275, 2015.

[26] Y. Han, F. Tanios, C. Reeps et al., “Histone acetylation and histone acetyltransferases show significant alterations in human abdominal aortic aneurysm,” Clinical Epigenetics, vol. 8, no. 1, p. 3, 2016.

[27] L. Mægdefessel, J. M. Spin, U. Raaz et al., “miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development,” Nature Communications, vol. 5, no. 1, p. 5214, 2014.

[28] K. S. Bishop and L. R. Ferguson, “The interaction between epigenetics, nutrition and the development of cancer,” Nutrients, vol. 7, no. 2, pp. 922–947, 2015.

[29] A. O. Caglayan and M. Dundar, “Inherited diseases and syndromes leading to aortic aneurysms and dissections,” European Journal of Cardio-Thoracic Surgery, vol. 35, no. 6, pp. 931–940, 2009.

[30] L. Y. Sakai, D. R. Keene, M. Renard, and J. De Backer, “The role of transforming growth factor-beta in Marfan syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 1, pp. 244–247, 2009.

[31] G. M. Longo, S. J. Buda, N. Fiotta et al., “MMP-12 has a role in abdominal aortic aneurysms in mice,” Surgery, vol. 137, no. 4, pp. 457–462, 2005.

[32] A. O. Caglayan and M. Dundar, “Inherited diseases and syndromes leading to aortic aneurysms and dissections,” European Journal of Cardio-Thoracic Surgery, vol. 35, no. 6, pp. 931–940, 2009.

[33] K. Benke, B. Agg, B. Szilveszter et al., “The role of transforming growth factor-beta in Marfan syndrome,” Cardiology Journal, vol. 20, no. 3, pp. 227–234, 2013.

[34] M. Frank, J. Albuisson, B. Ranque et al., “The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome,” European Journal of Human Genetics, vol. 23, no. 12, pp. 1657–1664, 2015.

[35] T. Freestone, R. J. Turner, A. Coady, D. J. Higman, R. M. Greenhalgh, and J. T. Powell, “Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 8, pp. 1145–1151, 1995.

[36] V. Davis, R. Persidskaia, L. Baca-Regen et al., “Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 10, pp. 1625–1633, 1998.
[35] C. Saracini, P. Bolli, E. Sticchi et al., “Polymorphisms of genes involved in extracellular matrix remodeling and abdominal aortic aneurysm,” Journal of Vascular Surgery, vol. 55, no. 1, pp. 171–179, 2012, e2.

[36] G. Makrygiannis, E. Mourmoua, K. Spanos et al., “Risk factor assessment in a Greek cohort of patients with large abdominal aortic aneurysms,” Angiology, vol. 70, no. 1, pp. 35–40, 2019.

[37] G. T. Jones, G. Tromp, H. Kuivaniemi et al., “Meta-analysis of genome-wide association studies for abdominal aortic aneurysm identifies four new disease-specific risk loci,” Circulation Research, vol. 120, no. 2, pp. 341–353, 2017.

[38] M. Abu-Farha, S. Lanouette, F. Elisma et al., “Extensive proteomic analyses of the SMYD family interactorome identify HSP90 as a novel target for SMYD2,” Journal of Molecular Cell Biology, vol. 3, no. 5, pp. 301–308, 2011.

[39] W. Tang, A. Saratzis, J. Pattee et al., “Replication of newly identified genetic associations between abdominal aortic aneurysm and SMYD2, LINC00540, PCIF1/MMP9/ZNF335, and ERG,” European Journal of Vascular and Endovascular Surgery, vol. 59, no. 1, pp. 92–97, 2020.

[40] B. J. Toghill, A. Saratzis, P. J. Freeman, N. Sylvius, and M. J. Bown, “SMYD2 promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) and SMYD2 expression in vascular smooth muscle cells,” Clinical Epigenetics, vol. 10, p. 29, 2018.

[41] J. D. Wythe, L. T. Dang, W. P. Devine et al., “ETS factors regulate Vegf-dependent arterial specification,” Developmental Cell, vol. 26, no. 1, pp. 45–58, 2013.

[42] J. Marsman, G. Gimenez, R. C. Day, J. A. Horsfield, and G. T. Jones, “A non-coding genetic variant associated with abdominal aortic aneurysm alters egr gene regulation,” Human Molecular Genetics, vol. 29, no. 4, pp. 554–565, 2020.

[43] A. Brunet and S. L. Berger, “Epi leakage of aging and aging-related disease,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 69, Suppl 1, pp. S17–S20, 2014.

[44] P. van der Harst, L. J. de Windt, and J. C. Chambers, “Translational perspective on epigenetics in cardiovascular disease,” Journal of the American College of Cardiology, vol. 70, no. 5, pp. 590–606, 2017.

[45] G. Natoli, “Maintaining cell identity through global control of genomic organization,” Immunity, vol. 33, no. 1, pp. 12–24, 2010.

[46] Q. Xia, J. Zhang, Y. Han et al., “Epigenetic regulation of regulatory T cells in patients with abdominal aortic aneurysm,” FEBS Open Bio, vol. 9, no. 6, pp. 1137–1143, 2019.

[47] H. Jiang, Q. Xia, S. Xin et al., “Abnormal epigenetic modifications in peripheral T cells from patients with abdominal aortic aneurysm are correlated with disease development,” Journal of Vascular Research, vol. 52, no. 6, pp. 404–413, 2016.

[48] L. D. Moore, T. Le, and G. Fan, “DNA methylation and its basic function,” Neuropsychopharmacology, vol. 38, no. 1, pp. 23–38, 2013.

[49] M. Skorovanova, T. Matakova, M. Skerenova et al., “Methylation of MMP2, TIMP2, MMP9 and TIMP1 in abdominal aortic aneurysm,” Bratislavské Lekárske Listy, vol. 121, no. 10, pp. 717–721, 2020.

[50] T. F. Whayne, “Epi leakage of cardiovascular disease,” Molecular Biology Reports, vol. 42, no. 4, pp. 765–776, 2015.

[51] M. Galán, S. Varona, M. Orrilo et al., “Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors,” Disease Models & Mechanisms, vol. 9, no. 5, pp. 541–552, 2016.

[52] H. Z. Chen, F. Wang, P. Gao et al., “Age-associated siruin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm,” Circulation Research, vol. 119, no. 10, pp. 1076–1088, 2016.

[53] D. Y. Li, A. Busch, H. Jin et al., “H19 induces abdominal aortic aneurysm development and progression,” Circulation, vol. 138, no. 15, pp. 1551–1568, 2018.

[54] X. He, S. Wang, M. Li et al., “Long noncoding RNA GAS5 induces abdominal aortic aneurysm formation by promoting smooth muscle apoptosis,” Theranostics, vol. 9, no. 19, pp. 5558–5576, 2019.

[55] Y. Sun, L. Zhong, X. He et al., “LncRNA H19 promotes vascular inflammation and abdominal aortic aneurysm formation by functioning as a competing endogenous RNA,” Journal of Molecular and Cellular Cardiology, vol. 131, pp. 66–81, 2019.

[56] S. Kumar, R. A. Boon, L. Maegdefessel, S. Dimmel er, and H. Jo, “Role of noncoding RNAs in the pathogenesis of abdominal aortic aneurysm,” Circulation Research, vol. 124, no. 4, pp. 619–630, 2019.

[57] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.

[58] K. Saliminejad, H. R. Khorram Khorshid, S. Soleymani Fard, and S. H. Ghaffari, “An overview of microRNAs: biology, functions, therapeutics, and analysis methods,” Journal of Cellular Physiology, vol. 234, no. 5, pp. 5451–5465, 2019.

[59] T. X. Lu and M. E. Rothenberg, “MicroRNA,” The Journal of Allergy and Clinical Immunology, vol. 141, no. 4, pp. 1202–1207, 2018.

[60] C. Schulte, M. Karakas, and T. Zeller, “MicroRNAs in cardiovascular disease - clinical application,” Clinical Chemistry and Laboratory Medicine, vol. 55, no. 5, pp. 687–704, 2017.

[61] R. A. Boon and S. Dimmel er, “MicroRNAs and aneurysm formation,” Trends in Cardiovascular Medicine, vol. 21, no. 6, pp. 172–177, 2011.

[62] A. Liu, Y. Liu, B. Li, M. Yang, Y. Liu, and J. Su, “Role of miR-223-3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway,” Cell Proliferation, vol. 52, no. 2, article e12550, 2019.

[63] L. Shi, C. Yu, X. Tian et al., “Effect of microRNA-133a-3p/matrix metalloproteinase-9 axis on the growth of atherosclerotic vascular smooth muscle cells,” Experimental and Therapeutic Medicine, vol. 18, no. 6, pp. 4356–4362, 2019.

[64] T. Nakao, T. Horie, O. Baba et al., “Genetic ablation of microRNA-33 attenuates inflammation and abdominal aortic aneurysm formation via several anti-inflammatory pathways,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 37, no. 11, pp. 2161–2170, 2017.

[65] Y. Sun, Y. U. Xiao, H. Sun et al., “miR-27a regulates vascular remodeling by targeting endothelial cells’ apoptosis and interaction with vascular smooth muscle cells in aortic dissection,” Theranostics, vol. 9, no. 25, pp. 7961–7975, 2019.

[66] L. Maegdefessel, J. Azuma, R. Toh et al., “Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development,” The Journal of Clinical Investigation, vol. 122, no. 2, pp. 497–506, 2012.
D. R. Merk, J. T. Chin, B. A. Dake et al., “miR-29b participates in early aneurysm development in Marfan syndrome,” *Circulation Research*, vol. 110, no. 2, pp. 312–324, 2012.

L. Maegdefessel, J. Azuma, R. Toh et al., “MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion,” *Science translational medicine*, vol. 4, no. 122, article 122ra22, 2012.

D. Wang, T. Deuse, M. Stubbendorf et al., “Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 35, no. 9, pp. 1945–1953, 2015.

L. Zhao, J. Huang, Y. Zhu et al., “miR-33-5p knockdown attenuates abdominal aortic aneurysm progression via promoting target adenosine triphosphate-binding cassette transporter A1 expression and activating the PI3K/Akt signaling pathway,” *Perfusion*, vol. 35, no. 1, pp. 57–65, 2020.

R. A. Boon, N. Jaé, L. Holdt, and S. Dimmeler, “Long noncoding RNAs: from clinical genetics to therapeutic targets?,” *Nature Reviews. Molecular Cell Biology*, vol. 17, no. 1, p. 271, 2017.

Y. Alsiraj, S. E. Thatcher, R. Charnigo et al., “Female mice with an XY sex chromosome complement develop severe angiotensin II-induced abdominal aortic aneurysms,” *Circulation*, vol. 135, no. 4, pp. 379–391, 2017.

K. Di Gregoli, N. N. Mohamad Anuar, R. Bianco et al., “MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin,” *Circulation Research*, vol. 120, no. 1, pp. 49–65, 2017.

P. Gao, J. Si, B. Yang, and J. Yu, “Upregulation of microRNA-15a contributes to pathogenesis of abdominal aortic aneurysm (AAA) by modulating the expression of cyclin-dependent kinase inhibitor 2B (CDKN2B),” *Medical Science Monitor*, vol. 23, pp. 881–888, 2017.

J. Wang, H. Sun, Y. Zhou et al., “Circular RNA microarray expression profile in 3,4-benzopyrene/angiotensin II-induced abdominal aortic aneurysm in mice,” *Journal of Cellular Biochemistry*, vol. 120, no. 6, pp. 10484–10494, 2019.

R. Yang, Z. Wang, G. Meng, and L. Hua, “Circular RNA CCDC66 facilitates abdominal aortic aneurysm through the overexpression of CCDC66,” *Cell Biochemistry and Function*, vol. 38, no. 7, pp. 830–838, 2020.

J. Yue, T. Zhu, J. Yang et al., “CircCBFB-mediated miR-28-5p facilitates abdominal aortic aneurysm via LYPD3 and GRIA4,” *Life Sciences*, vol. 253, p. 117533, 2020.

S. Memczak, M. Jens, A. Elefsinioti et al., “Circular RNAs are a large class of animal RNAs with regulatory potency,” *Nature*, vol. 495, no. 7441, pp. 333–338, 2013.

F. Zhao, T. Chen, and N. Jiang, “CDR1as/miR-7/CAP4P axis contributes to the pathogenesis of abdominal aortic aneurysm by regulating the proliferation and apoptosis of primary vascular smooth muscle cells,” *Experimental and Therapeutic Medicine*, vol. 19, no. 6, pp. 3760–3766, 2020.

C. Zheng, H. Niu, M. Li et al., “Cyclic RNA hsa-circ-000595 regulates apoptosis of aortic smooth muscle cells,” *Molecular Medicine Reports*, vol. 12, no. 5, pp. 6656–6662, 2015.

J. Zhou, Y. S. Li, and S. Chien, “Shear stress-initiated signaling and its regulation of endothelial function,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 34, no. 10, pp. 2191–2198, 2014.

I. Hinterseher, R. Erdman, L. A. Donoso et al., “Role of component cascade in abdominal aortic aneurysms,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 7, pp. 1653–1660, 2011.
[98] M. R. Alexander and G. K. Owens, “Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease,” *Annual Review of Physiology*, vol. 74, pp. 13–40, 2012.

[99] A. Palazzuoli, M. Gallotta, G. Guerrieri et al., “Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: comparison with high cardiovascular risk population,” *Vascular Health and Risk Management*, vol. 4, no. 4, pp. 877–883, 2008.

[100] B. J. Toghill, A. Saratzis, and M. J. Bown, “Abdominal aortic aneurysm—an independent disease at atherosclerosis?,” *Cardiovascular Pathology*, vol. 27, pp. 71–75, 2017.

[101] S. H. Tsai, P. H. Huang, Y. J. Hsu et al., “Inhibition of hypoxia inducible factor-1alpha attenuates abdominal aortic aneurysm progression through the down-regulation of matrix metalloproteinases,” *Scientific Reports*, vol. 6, p. 28612, 2016.

[102] W. Hauzer, W. Witkiewicz, and J. Gnus, “Calprotectin and receptor for advanced glycation end products as a potential biomarker in abdominal aortic aneurysm,” *Journal of Clinical Medicine*, vol. 9, no. 4, 2020.

[103] T. I. Emeto, J. V. Moxon, M. Au, and J. Golledge, “Oxidative stress and abdominal aortic aneurysm: potential treatment targets,” *Clinical Science (London, England)*, vol. 130, no. 5, pp. 301–315, 2016.

[104] L. Gutowski, K. Gutowska, M. Pioruńska-Stolzmann, P. Formanowicz, and D. Formanowicz, “Systems approach to study associations between OxLDL and abdominal aortic aneurysms,” *International Journal of Molecular Sciences*, vol. 20, no. 16, 2019.

[105] R. Batra, M. K. Sub, J. S. Carson et al., “IL-1beta (interleukin-1beta) and TNF-alpha (tumor necrosis factor-alpha) impact abdominal aortic aneurysm formation by differential effects on macrophage polarization,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 38, no. 2, pp. 457–463, 2018.

[106] T. Blassova, Z. Tonar, P. Tomasek et al., “Inflammatory cell infiltrates, hypoxia, vascularization, pentraxin 3 and osteo-protegerin in abdominal aortic aneurysms - a quantitative histological study,” *PLoS One*, vol. 14, no. 11, article e0224819, 2018.

[107] R. Y. Dang, F. L. Liu, and Y. Li, “Circular RNA hsa_circ_0010729 regulates vascular endothelial cell proliferation and apoptosis by targeting the miR-186/HIF-1alpha axis,” *Biochemical and Biophysical Research Communications*, vol. 490, no. 2, pp. 104–110, 2017.

[108] H. G. Wang, H. Yan, C. Wang et al., “circAFF1 aggravates vascular endothelial cell dysfunction mediated by miR-516b/SAV1/YAP1 axis,” *Frontiers in Physiology*, vol. 11, p. 899, 2020.

[109] C. Liu, M. D. Yao, C. P. Li et al., “Silencing of circular RNA-ZNF609 ameliorates vascular endothelial dysfunction,” *Theranostics*, vol. 7, no. 11, pp. 2863–2877, 2017.

[110] F. Zhang, K. C. Kent, Y. Z. Dai Yamanouchi et al., “Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm,” *Annals of Surgery*, vol. 250, no. 3, pp. 416–423, 2009.

[111] K. Prasad, “AGE-RAGE stress play a role in aortic aneurysm: a comprehensive review and novel potential therapeutic target,” *Reviews in Cardiovascular Medicine*, vol. 20, no. 4, pp. 201–208, 2019.

[112] J. Sun, Y. Pu, P. Wang et al., “TRPV1-mediated UCP2 upregulation ameliorates hyperglycemia-induced endothelial dys-function,” *Cardiovascular Diabetology*, vol. 12, no. 1, p. 69, 2013.

[113] W. Zhang and Y. Sui, “CircBPTF knockdown ameliorates high glucose-induced inflammatory injuries and oxidative stress by targeting the miR-384/LIN28B axis in human umbilical vein endothelial cells,” *Molecular and Cellular Biochemistry*, vol. 471, no. 1–2, pp. 101–111, 2020.

[114] J. Cheng, Q. Liu, N. Hu et al., “Downregulation of hsa_circ_0068087 ameliorates TLR4/NF-kB/NLRP3 inflammasome-mediated inflammation and endothelial cell dysfunction in high glucose conditioned by sponging miR-197,” *Gene*, vol. 709, pp. 1–7, 2019.

[115] L. Pan, W. Lian, X. Zhang et al., “Human circular RNA-0054633 regulates high glucose-induced vascular endothelial cell dysfunction through the microRNA-218/round-about 1 and microRNA-218/heme oxygenase-1 axes,” *International Journal of Molecular Medicine*, vol. 42, no. 1, pp. 597–606, 2018.

[116] Y. Cao, G. Yuan, Y. Zhang, and R. Lu, “High glucose-induced circHIPK3 downregulation mediates endothelial cell injury,” *Biochemical and Biophysical Research Communications*, vol. 507, no. 1–4, pp. 362–368, 2018.

[117] J. R. Hickok, D. Vasudevan, K. Jablonski, and D. D. Thomas, “Oxidation dependent of nitric oxide-mediated signaling,” *Redox Biology*, vol. 1, pp. 203–209, 2013.

[118] U. Simonsen, R. Rodriguez-Rodriguez, T. Dalsgaard, N. H. Buus, and E. Stankevicius, “Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilation,” *Pharmacological Reports*, vol. 61, no. 1, pp. 105–115, 2009.

[119] H. X. Li, F. J. Kong, S. Z. Bai et al., “Involvement of calcium-sensing receptor in oxLDL-induced MMP-2 production in vascular smooth muscle cells via PI3K/Akt pathway,” *Molecular and Cellular Biochemistry*, vol. 362, no. 1–2, pp. 115–122, 2012.

[120] F. Chang, S. Flavahan, and N. A. Flavahan, “Superoxide inhibition restores endothelium-dependent dilatation in aging arteries by enhancing impaired adherens junctions,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 314, no. 4, pp. H805–H811, 2018.

[121] S. Zhang, G. Song, J. Yuan et al., “Circular RNA circ_0003204 inhibits proliferation, migration and tube formation of endothelial cell in atherosclerosis via miR-370-3p/TGFbetaR2/phosph-SMAD3 axis,” *Journal of Biomedical Science*, vol. 27, no. 1, p. 11, 2020.

[122] H. Liu, X. Ma, Z. Mao, M. Shen, J. Zhu, and F. Chen, “Circular RNA has_circ_0003204 inhibits oxLDL-induced vascular endothelial cell proliferation and angiogenesis,” *Cellular Signalling*, vol. 70, p. 109595, 2020.

[123] G. Wang, Y. Li, Z. Liu et al., “Circular RNA circ_0124644 exacerbates the ox-LDL-induced endothelial injury in human vascular endothelial cells through regulating PAPP-A by acting as a sponge of miR-149-5p,” *Molecular and Cellular Biochemistry*, vol. 471, no. 1–2, pp. 51–61, 2020.

[124] M. Qin, W. Wang, H. Zhou, X. Wang, F. Wang, and H. Wang, “Circular RNA circ_0003645 silencing alleviates inflammation and apoptosis via the NF-kappaB pathway in endothelial cells induced by oxLDL,” *Gene*, vol. 755, pp. 144900, 2020.

[125] P. Ding, Y. Ding, Y. Tian, and X. Lei, “Circular RNA circ_0010283 regulates the viability and migration of oxidized low-density lipoprotein-induced vascular smooth muscle
cells via an miR-370-3p/HMGBl axis in atherosclerosis,” *International Journal of Molecular Medicine*, vol. 46, no. 4, pp. 1399–1408, 2020.

[126] Z. Feng, Y. Zhu, J. Zhang, W. Yang, Z. Chen, and B. Li, “Hsa-circ_0010283 regulates oxidized low-density lipoprotein-induced proliferation and migration of vascular smooth muscle cells by targeting the miR-133a-3p/pregnancy-associated plasma protein A axis,” *Circulation Journal*, vol. 84, no. 12, pp. 2259–2269, 2020.

[127] L. Yang, F. Yang, H. Zhao, M. Wang, and Y. Zhang, “Circular RNA circCHFR facilitates the proliferation and migration of vascular smooth muscle via miR-370/FOXO1/Cyclin D1 pathway,” *Molecular Therapy-Nucleic Acids*, vol. 16, pp. 434–441, 2019.

[128] J. B. Zhuang, T. Li, X. M. Hu et al., “Circ_CHFR expedites cell growth, migration and inflammation in ox-LDL-treated human vascular smooth muscle cells via the miR-214-3p/Wnt3/beta-catenin pathway,” *European Review for Medical and Pharmacological Sciences*, vol. 24, no. 6, pp. 3282–3292, 2020.

[129] H. Yu, L. Zhao, Y. Zhao, J. Fei, and W. Zhang, “Circular RNA circ_0029589 regulates proliferation, migration, invasion, and apoptosis in ox-LDL-stimulated VSMCs by regulating miR-424-5p/IGF2 axis,” *Vascular Pharmacology*, vol. 135, p. 106782, 2020.

[130] Z. Huang, P. Li, L. Wu et al., “Hsa_circ_0029589 knockdown inhibits the proliferation, migration and invasion of vascular smooth muscle cells via regulating miR-214-3p and STIM1,” *Life Sciences*, vol. 259, p. 118251, 2020.

[131] Y. Sun, S. Zhang, M. Yue, Y. Li, J. Bi, and H. Liu, “Angiotensin II inhibits apoptosis of mouse aortic smooth muscle cells through regulating the circNRG-1/miR-193b-5p/NRG-1 axis,” *Cell Death & Disease*, vol. 10, no. 5, p. 362, 2019.

[132] S. Wang, J. Zhan, X. Lin, Y. Wang, Y. Wang, and Y. Liu, “CircRNA-0077930 from hyperglycaemia-stimulated vascular endothelial cell exosomes regulates senescence in vascular smooth muscle cells,” *Cell Biochemistry and Function*, vol. 38, no. 8, pp. 1056–1068, 2020.

[133] L. Shen, Y. Hu, J. Lou et al., “CircRNA-0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR-107,” *Molecular Medicine Reports*, vol. 19, no. 5, pp. 3923–3932, 2019.

[134] P. Kong, Y. Yu, L. Wang et al., “circ-Sirt1 controls NF-kappaB activation via sequence-specific interaction and enhancement of SIRT1 expression by binding to miR-132/212 in vascular smooth muscle cells,” *Nucleic Acids Research*, vol. 47, no. 7, pp. 3580–3593, 2019.

[135] W. Peng, T. Li, S. Pi, L. Huang, and Y. Liu, “Suppression of circular RNA circDHCR24 alleviates aortic smooth muscle cell proliferation and migration by targeting miR-149-5p/MMP9 axis,” *Biochemical and Biophysical Research Communications*, vol. 529, no. 3, pp. 753–759, 2020.

[136] Y. Y. Mao, J. Q. Wang, X. X. Guo, Y. Bi, and C. X. Wang, “Circ-SATB2 upregulates STIM1 expression and regulates vascular smooth muscle cell proliferation and differentiation through miR-939,” *Biochemical and Biophysical Research Communications*, vol. 505, no. 1, pp. 119–125, 2018.

[137] J. Sun, Z. Zhang, and S. Yang, “Circ_RUSC2 upregulates the expression of miR-661 target gene SYK and regulates the function of vascular smooth muscle cells,” *Biochemistry and Cell Biology*, vol. 97, no. 6, pp. 709–714, 2019.

[138] X. Lu, Y. Liu, W. Xuan et al., “Circ_1639 induces cells inflammation responses by sponging miR-122 and regulating TNFRSF13C expression in alcoholic liver disease,” *Toxicology Letters*, vol. 314, pp. 89–97, 2019.

[139] T. Deng, L. Yang, Z. Zheng et al., “Calcitonin generelated peptide induces IL6 expression in RAW264.7 macrophages mediated by mmu_circRNA_007893,” *Molecular Medicine Reports*, vol. 16, no. 6, pp. 9367–9374, 2017.

[140] M. Zou, C. Huang, X. Li et al., “Circular RNA expression profile and potential function of hsa_circRNA_101238 in human thoracic aortic dissection,” *Oncotarget*, vol. 8, no. 47, pp. 81825–81837, 2017.

[141] N. J. Leeper, A. Ratesdana, Y. Kojima et al., “MicroRNA-26a is a novel regulator of vascular smooth muscle cell function,” *Journal of Cellular Physiology*, vol. 226, no. 4, pp. 1035–1043, 2011.

[142] L. M. Holdt, A. Stahringer, K. Sass et al., “Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans,” *Nature Communications*, vol. 7, p. 12429, 2016.

[143] C. Tian, X. Tang, X. Zhu et al., “Expression profiles of circRNAs and the potential diagnostic value of serum circ-MARK3 in human acute Stanford type A aortic dissection,” *PloS One*, vol. 14, no. 6, article e0219013, 2019.

[144] L. Teng, Y. U. Chen, H. Chen et al., “Circular RNA hsa_circ_0021001 in peripheral blood: a potential novel biomarker in the screening of intracranial aneurysm,” *Oncotarget*, vol. 8, no. 63, pp. 107125–107133, 2017.

[145] Q. Huang, Q. Y. Huang, Y. Sun, and S. Y. Wu, “High-throughput data reveals novel circular RNAs via competitive endogenous RNA networks associated with human intracranial aneurysms,” *Medical Science Monitor*, vol. 25, pp. 4819–4830, 2019.

[146] Y. Wang, Y. Wang, Y. Li et al., “Decreased expression of circ_0020397 in intracranial aneurysms may be contributing to decreased vascular smooth muscle cell proliferation via increased expression of miR-138 and subsequent decreased KDR expression,” *Cell Adhesion & Migration*, vol. 13, no. 1, pp. 220–228, 2019.